Pacira Pharma (PCRX) Tops Q4 EPS by 19c

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.47, $0.19 better than the analyst estimate of $0.28. Revenue for the quarter came in at $95.1 million versus the consensus estimate of $93.69 million.

Pacira announces its full year 2019 financial guidance as follows. Pacira expects:

• EXPAREL net product sales of $400 million to $410 million.
• Non-GAAP gross margins of 75% to 76%.
• Non-GAAP research and development (R&D) expense of $60 million to $70 million.
• Non-GAAP selling, general and administrative (SG&A) expense of $165 million to $175 million.
• Stock-based compensation of $30 million to $35 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance